Amended Statement of Ownership (sc 13g/a)
January 02 2019 - 9:14AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION
Washington, DC 20549
SCHEDULE 13G/A
Under the Securities Exchange Act of 1934
(Amendment No. 2)*
|
Adamas Pharmaceuticals, Inc.
|
|
(Name of Issuer)
|
|
|
|
Common
Stock, par value $0.001 per share
|
|
(Title of Class of Securities)
|
|
|
|
00548A106
|
|
(CUSIP Number)
|
|
|
|
December
31, 2018**
|
|
(Date of Event Which Requires Filing of this Statement)
|
Check the appropriate box to designate the
rule pursuant to which this Schedule is filed:
x
Rule
13d-1(b)
o
Rule
13d-1(c)
o
Rule
13d-1(d)
*The remainder of this cover page shall be
filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for
any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder of
this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934
(“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions
of the Act (however, see the Notes).
**The firm ceased conducting advisory
business as of December 17, 2018.
|
CUSIP No. 00548A106
|
SCHEDULE 13G/A
|
Page 2
of 9 Pages
|
|
|
|
|
|
|
|
1
|
NAME OF REPORTING
PERSONS
Brenner West Capital Advisors, LP
|
|
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a)
x
(b)
o
|
|
|
3
|
SEC USE ONLY
|
|
4
|
CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware, United States
|
|
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
|
5
|
SOLE VOTING POWER
0
|
|
6
|
SHARED VOTING POWER
0
|
|
7
|
SOLE DISPOSITIVE POWER
0
|
|
8
|
SHARED DISPOSITIVE POWER
0
|
|
9
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
0
|
|
10
|
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
|
o
|
|
11
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
0%
|
|
12
|
TYPE OF REPORTING PERSON
IA, PN
|
|
CUSIP No. 00548A106
|
SCHEDULE 13G/A
|
Page 3
of 9 Pages
|
|
|
|
|
|
|
|
1
|
NAME OF REPORTING
PERSONS
Craig Nerenberg
|
|
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a)
x
(b)
o
|
|
|
3
|
SEC USE ONLY
|
|
4
|
CITIZENSHIP OR PLACE OF ORGANIZATION
United States
|
|
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
|
5
|
SOLE VOTING POWER
0
|
|
6
|
SHARED VOTING POWER
0
|
|
7
|
SOLE DISPOSITIVE POWER
0
|
|
8
|
SHARED DISPOSITIVE POWER
0
|
|
9
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
0
|
|
10
|
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
|
o
|
|
11
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
0%
|
|
12
|
TYPE OF REPORTING PERSON
IN, HC
|
|
CUSIP No. 00548A106
|
SCHEDULE 13G/A
|
Page 4
of 9 Pages
|
|
|
|
|
|
|
|
1
|
NAME OF REPORTING
PERSONS
Josh Kaufman
|
|
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a)
x
(b)
o
|
|
|
3
|
SEC USE ONLY
|
|
4
|
CITIZENSHIP OR PLACE OF ORGANIZATION
United States
|
|
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
|
5
|
SOLE VOTING POWER
0
|
|
6
|
SHARED VOTING POWER
0
|
|
7
|
SOLE DISPOSITIVE POWER
0
|
|
8
|
SHARED DISPOSITIVE POWER
0
|
|
9
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
0
|
|
10
|
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
|
o
|
|
11
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
0%
|
|
12
|
TYPE OF REPORTING PERSON
IN, HC
|
|
CUSIP No. 00548A106
|
SCHEDULE 13G/A
|
Page
5 of 9 Pages
|
|
Item 1.
|
|
(a) Name of Issuer
|
Adamas Pharmaceuticals, Inc.
|
|
|
(b) Address of Issuer’s Principal
Executive Offices
|
1900 Powell Street, Suite 750
Emeryville,
CA 94608
|
Item 2.
|
|
(a) Name of Person Filing
|
This statement is filed by:
(i)
Brenner West Capital Advisors, LP (“Brenner West”), a Delaware limited partnership that serves as investment manager
to certain funds and accounts (collectively, the “Funds”), with respect to the shares of Common Stock directly
owned by the Funds;
(ii)
Craig Nerenberg ("Mr. Nerenberg"), a Managing Member of Brenner West who, together with Mr. Kaufman, is primarily
responsible for managing the investments of the Funds, with respect to the shares of Common Stock directly owned by the
Funds; and
(iii)
Josh Kaufman ("Mr. Kaufman"), a Managing Member of Brenner West who, together with Mr. Nerenberg, is primarily responsible
for managing the investments of the Funds, with respect to the shares of Common Stock directly owned by the Funds.
The
foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons." Any disclosures herein with
respect to persons other than the Reporting Persons are made on information and belief after making inquiry to the
appropriate party.
|
|
|
(b) Address
of Principal Business Office, or, if none, Residence
|
The
address of the principal business office of Brenner West Capital Advisors, LP, Mr. Nerenberg and Mr. Kaufman is 500 Fifth Avenue,
41st Floor, New York, New York 10110.
Please
refer to Item 4 on each cover sheet for each Reporting Person.
|
|
|
(d) Title of Class of Securities
|
Common
Stock, par value $0.001 per share ( the “Common Stock”)
00548A106
|
CUSIP No. 00548A106
|
SCHEDULE 13G/A
|
Page 6
of 9 Pages
|
|
|
Item 3. If
this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
|
|
|
(a)
|
¨
|
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
|
|
|
|
|
(b)
|
¨
|
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
|
|
|
|
|
(c)
|
¨
|
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
|
|
|
|
|
(d)
|
¨
|
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
|
|
|
|
|
(e)
|
x
|
An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
|
|
|
|
|
(f)
|
¨
|
An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
|
|
|
|
|
(g)
|
x
|
A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
|
|
|
|
|
(h)
|
¨
|
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
|
|
|
|
|
(i)
|
¨
|
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the
Investment Company Act of 1940 (15 U.S.C. 80a-3);
|
|
|
|
|
(j)
|
¨
|
A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
|
|
|
|
|
(k)
|
¨
|
A group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
|
|
|
|
|
|
|
CUSIP No. 00548A106
|
SCHEDULE 13G/A
|
Page
7 of 9 Pages
|
Item
4. Ownership
Please
see Items 5 - 9 and 11 on each cover sheet for each Reporting Person. Brenner West and Messrs. Nerenberg and Kaufman disclaim
beneficial ownership of the Common Stock.
Item
5. Ownership of Five Percent or Less of a Class
If this statement is being filed to report the fact that as of the date hereof each of the Reporting Persons
has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ X].
Item
6. Ownership of More Than Five Percent on Behalf of Another Person
Not Applicable.
Item
7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent
Holding Company or Control Person
Not Applicable.
Item
8. Identification and Classification of Members of the Group
Not Applicable.
Item
9. Notice of Dissolution of Group
Not Applicable.
Item
10. Certification
By
signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held
in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or
influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant
in any transaction having that purpose or effect.
|
CUSIP No. 00548A106
|
SCHEDULE 13G/A
|
Page 8
of 9 Pages
|
SIGNATURE
After reasonable inquiry
and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Dated: January 2, 2019
|
|
|
|
Brenner
West Capital Advisors, LP
|
|
|
|
|
|
|
|
By:
|
/s/
Michael Weiss
|
|
|
|
Name: Michael Weiss
Title: Chief Operating Officer
|
|
|
|
|
|
|
|
Craig Nerenberg
|
|
|
|
|
|
|
|
By:
|
/s/
Craig Nerenberg
|
|
|
|
Name: Craig Nerenberg
|
|
|
|
|
|
|
Josh Kaufman
|
|
|
|
|
|
|
|
By:
|
/s/
Josh Kaufman
|
|
|
|
Name:
Josh Kaufman
|
|
|
|
|
|
|
CUSIP No. 00548A106
|
SCHEDULE 13G/A
|
Page 9
of 9 Pages
|
JOINT FILING AGREEMENT
PURSUANT TO RULE 13d-1(k)
The undersigned acknowledge and agree that the foregoing statement on Schedule 13G/A is filed on behalf of each of the undersigned
and that all subsequent amendments to this statement on Schedule 13G/A shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained
therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to
the extent that he or it knows or has reason to believe that such information is inaccurate.
Dated: January 2, 2019
|
|
|
|
Brenner
West Capital Advisors, LP
|
|
|
|
|
|
|
|
By:
|
/s/
Michael Weiss
|
|
|
|
Name: Michael Weiss
Title: Chief Operating Officer
|
|
|
|
|
|
|
|
Craig Nerenberg
|
|
|
|
|
|
|
|
By:
|
/s/
Craig Nerenberg
|
|
|
|
Name: Craig Nerenberg
|
|
|
Josh Kaufman
|
|
|
|
|
|
|
|
By:
|
/s/
Josh Kaufman
|
|
|
|
Name:
Josh Kaufman
|
Adamas Pharmaceuticals (NASDAQ:ADMS)
Historical Stock Chart
From Oct 2024 to Nov 2024
Adamas Pharmaceuticals (NASDAQ:ADMS)
Historical Stock Chart
From Nov 2023 to Nov 2024
See More Message Board Posts
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.